This corrects the article: “Ioannou A. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. Heart International. 2024;18(1):30-37”.
Two typography errors were included incorrectly due to an editorial error.
In Table 1, “eplontersen” was incorrectly written as “eplomtersen”. This has been corrected in the text.
In the section “Eplontersen”, the administration schedule should be written as every 4 weeks, rather than every 3 weeks, as per the correct information provided in Table 1. This has been corrected in the text as follows:
“This superior delivery system has enabled eplontersen to be up to 50-fold more potent than inotersen at reducing TTR expression, which in turn allows it to be administered every 4 weeks, rather than the weekly subcutaneous injection required to administer inotersen.58”
